STAT3 and colorectal carcinoma: Based on the TCGA CRC cohort, we carried out a GSEA analysis to explore the difference between TNM stage I/II CRC patients in cluster-1 and cluster-2, and the results showed that gene sets of HALLMARK_INFLAMMATORY_RESPONSE, HALLMARK_COMPLEMENT, HALLMARK_INTERFERON_GAMMA_RESPONSE, HALLMARK_INTERFERON_ALPHA_RESPONSE, HALLMARK_ALLOGRAFT_REJECTION, HALLMARK_IL6_JAK_STAT3_SIGNALING, HALLMARK_IL2_STAT5_SIGNALING, and HALLMARK_INFLAMMATORY_RESPONSE were positively enriched in CRC patients in cluster-2 (Figure 3A).